CClinicalTrials.gg
RecruitingNCT06450353Updated Jul 16, 2026

Prospective Evaluation of Disparities in Provision of Allogeneic Transplantation

An observational study in Allogeneic Transplantation, sponsored by M.D. Anderson Cancer Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-16.

Sponsored by M.D. Anderson Cancer Center · Observational

From the registry’s dates

  • Started May 2024; still recruiting 2 years 4 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,200
Ages
18 Years and older
Sex
All
01

Study summary

To look at the effect of a recipient's ancestry and socio-economic status on their choice of bone marrow transplantation donor cells and their chance of receiving genetically similar (allogeneic) bone marrow cells versus cells that are not genetically similar (allograft).

Read the detailed description

Primary Objectives To prospectively evaluate graft options and choice of donor by patient ancestry and SES for allograft candidates at MDACC.

Secondary Objectives

  • To prospectively evaluate time to transplant for allograft candidates at MDACC.
  • To evaluate treatment-related mortality for allograft candidates at MDACC.
  • To assess overall survival for allograft candidates at MDACC.
  • To prospectively evaluate receipt of preferred unrelated donor for allograft recipients at MDACC.
  • To evaluate receipt of an optimal graft for allograft recipients at MDACC.
02

Conditions studied

  • Allogeneic Transplantation
03

In context

Lead sponsor

M.D. Anderson Cancer Center is the lead sponsor of 2,999 studies on the registry; 581 are open to participants now.

Of its 599 completed or terminated interventional studies of FDA-regulated products, 402 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

MD Anderson Cancer Center

Inclusion criteria

  1. ≥ 18 years of age.
  2. Candidate for allogeneic transplantation

Exclusion criteria

Exclusion Criteria:

1) Allogeneic stem cell transplantation not medically indicated.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,200 participants (estimated)
Patient registry
No

Groups and cohorts

  • Prospective evaluation

    Participants are expected to be in this research study for up to 2 years after the participants bone marrow transplantation. However, your active participation will only last 1 day, when you sign the consent form and complete a questionnaire about your demographic information and ancestry (family ethnicity). For the rest of the study, information about the participants medical history, choice of bone marrow donor, and health outcomes will be collected from your medical record.

    Behavioral: Patient Ancestry Questionnaires

Interventions

  • BehavioralPatient Ancestry Questionnaires

    Participants will be asked to complete a demographics and ancestry questionnaire at the baseline visit before you and your doctor select bone marrow donation candidates.

06

What researchers measure

Primary outcomes

  1. Patient Ancestry Questionnaire

    Time frame: Through study completion; an average of 1 year.

07

Study locations

1 of 1 sites recruiting
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
    Recruiting
08

References and documents

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06450353
Lead sponsor
M.D. Anderson Cancer Center
Responsible party
Sponsor
First posted
Jun 10, 2024
Start date
May 31, 2024
Primary completion
Jun 1, 2027 (estimated)
Completion
Jun 1, 2029 (estimated)
Last update
Jul 16, 2026

Study contacts

Warren Fingrut, MD
Contact
wbfingrut@mdanderson.org
(832) 387-8363
Warren Fingrut, MD
principal investigator · M.D. Anderson Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion